NCT05548296Phase 2Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-05-30Estimated

Enrollment · participants350Estimated

Source updated2026-08-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-11 · 1 field changed

Enrollment · participant count

Recorded edit

− Previous value

+ Updated value

Check registry source

Posted 2026-05-05 · 3 fields changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.; measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.; measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).

+ Updated value

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit

− Previous value

+ Updated value

Primary completion date

Recorded edit

− Previous value

2026-10-31

+ Updated value

2027-05-30

Check registry source

Study details

Conditions studied

Endometrial Adenocarcinoma

Treatments or interventions studied

ACR-368DrugAlso known as prexasertib
GemcitabineDrug

Primary outcomes · main study measures

Read the study measures

measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.; description: Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.; timeFrame: Response will be assessed every 8 weeks from baseline through 2 years or death.; measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.; description: Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.; timeFrame: Response will be assessed every 8 weeks from baseline through 2 years or death.; measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).; description: Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.; timeFrame: Response will be assessed every 8 weeks from baseline through 2 years or death.; measure: Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).; description: Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic; timeFrame: Response will be assessed every 8 weeks from baseline through 2 years or death.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history